GSK says U.S. FDA approves kidney disease drug for children

[July 28, 2022]  (Reuters) -GSK Plc said on Wednesday the U.S. Food and Drug Administration had cleared its kidney disease drug Benlysta for the treatment of children aged 5 to 17 years.

The clearance makes Benlysta the first treatment approved by the U.S. regulator for children with lupus nephritis, a kind of kidney inflammation.

Lupus nephritis is a complication of an autoimmmune disease called lupus, which could lead to kidney damage and failure.

Signage is seen outside of the Food and Drug Administration (FDA) headquarters in White Oak, Maryland, U.S., August 29, 2020. REUTERS/Andrew Kelly/File Photo

Benlysta in 2020 received approval in the United States for adult patients with the disease.

(Reporting by Amruta Khandekar; Editing by Devika Syamnath)

[© 2022 Thomson Reuters. All rights reserved.] 

This material may not be published, broadcast, rewritten or redistributed.  Thompson Reuters is solely responsible for this content.